CD4 count and percentage

[Guest guest]

http://www.eatg.org/news/newsitem.php?id=959

Absolute CD4 cell count and CD4 percentage independently

predict HIV disease progression

Tuesday, February 13, 2007

CD4 percentage may be used as an additional factor to help determine the

optimal timing of HAART.

By Liz Highleyman

Absolute CD4 cell count is the most commonly monitored measure of immune

function in people with HIV. According to current U.S. federal HIV

treatment guidelines, antiretroviral therapy should be considered when a

person's CD4 count falls below 350 cells/mm3, while a level below 200

cells/mm3 indicates a diagnosis of AIDS.

However, CD4 cell percentage may also play a role in guiding decisions

about treatment, according to a study published in the February 1, 2007

issue of the Journal of Infectious Diseases. (A CD4 percentage of about

40% is considered normal.)

In the present study, researchers sought to characterize the predictive

utility of CD4 percentage. They performed an observational study of

participants in the Collaborations in HIV Outcomes Research/US (CHORUS)

cohort who started their first HAART regimen between 1997 and 2004 and

received at least 30 days of therapy.

Results

• The analysis included 1891 participants with a median age of 38 years;

89% were men, 72% were white, and 18% were African-American.

• Before starting HAART, the mean baseline CD4 cell count was 240

cells/mm3, the mean CD4 percentage was 16%, and 29% had progressed to

AIDS.

• After a follow-up period of 55 months (IQR 23-83 months), 468 subjects

(25%) experienced disease progression, defined as a new AIDS-defining

event or death.

• In a multivariable analysis including age, race, sex, HIV RNA level,

prior antiretroviral therapy, probable route of infection, prior

AIDS-defining events, absolute CD4 count, and CD4 percentage, the

following factors independently predicted disease progression:

- prior antiretroviral therapy (P < 0.0001);

- injection drug use (P = 0.04);

- lower baseline absolute CD4 cell count (P = 0.002);

- lower baseline CD4 cell percentage (P = 0.002).

Conclusion

In conclusion the authors wrote, " [CD4 percentage] at initiation of

the first HAART regimen predicted disease progression independent of

absolute CD4 [count]. "

In their discussion, the researchers noted that while both absolute CD4

cell count and CD4 percentage predicted disease progression, the 2

measures did not always correspond.

That is, some patients with relatively high absolute CD4 counts but low

CD4 percentages experienced more disease progression than subjects with

low CD4 cell counts but high CD4 percentages. For example, a patient with

a baseline absolute CD4 count of 350 cells/mm3 but a CD4 percentage of

14% was at higher risk of disease progression than one with an absolute

CD4 count of 200 cells/mm3 but a CD4 percentage of 28%. Moreover,

individuals with the same absolute CD4 counts had a variable risk of

progression depending on their CD4 percentages.

Thus, the authors said, CD4 percentage may be used as an additional

factor to help determine the optimal timing of HAART. These results

suggest that some patients with low CD4 percentages may benefit from

starting HAART earlier, even if their absolute CD4 counts are not yet at

the recommended threshold for initiating therapy.

Reference

T Hulgan, B E Shepard, S P Raffanti, and others. Absolute Count and

Percentage of CD4+ Lymphocytes Are Independent Predictors of Disease

Progression in HIV-Infected Persons Initiating Highly Active

Antiretroviral Therapy. Journal of Infectious Diseases 195(3): 425-431.

February 1, 2007.

SOURCE: HIV and

Hepatitis.com

http://www.hivandhepatitis.com/recent/2007/021307_b.html